GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Common Stock

Lumos Diagnostics Holdings (ASX:LDX) Common Stock : A$147.93 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Common Stock?

Lumos Diagnostics Holdings's quarterly common stock increased from Jun. 2023 (A$137.78 Mil) to Dec. 2023 (A$146.75 Mil) and increased from Dec. 2023 (A$146.75 Mil) to Jun. 2024 (A$147.93 Mil).

Lumos Diagnostics Holdings's annual common stock increased from Jun. 2022 (A$131.11 Mil) to Jun. 2023 (A$137.78 Mil) and increased from Jun. 2023 (A$137.78 Mil) to Jun. 2024 (A$147.93 Mil).


Lumos Diagnostics Holdings Common Stock Historical Data

The historical data trend for Lumos Diagnostics Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Common Stock Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24
Common Stock
131.11 137.78 147.93

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial 131.11 136.58 137.78 146.75 147.93

Lumos Diagnostics Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Lumos Diagnostics Holdings Business Description

Traded in Other Exchanges
Address
2724 Loker Ave West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings Headlines

No Headlines